An award-winning journalist, Derrick has written extensively about user fee negotiations, the FDA budget, FDA travel restrictions and drug advertising compliance. He also was part of the Pink Sheet team covering FDA's first biosimilar advisory committee meetings.
When he's not following FDA, Derrick is keeping close tabs on Indiana Hoosiers basketball.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Derrick Gingery
As part of the new Coronavirus Treatment Acceleration Program, FDA staff also are being reassigned to handle investigational therapy requests faster.
Office of New Drugs Director Peter Stein said in an interview that a large amount of coronavirus-related work is arriving at the FDA, but so far staff are keeping up.
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.
What's in – and what fell out of – the massive US stimulus package.
Agency appears to have a fair bit of flexibility in how to spend the additional $80m slated for coronavirus activities.
An additional $160m is allocated to FDA in House coronavirus-related stimulus bill aimed at fighting the pandemic and helping the wobbling economy. It would not, as a similar Senate bill proposes, once again allow using pre-tax savings accounts to buy OTC drugs.